CIK 0001439725
- Non-accelerated filer
- Smaller reporting company
BIODESIX INC
Sign in to watch- Ticker
- BDSX
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 203986492
- Phone
- +1 303-417-0500
- Business address
- 919 WEST DILLON ROAD, LOUISVILLE, CO, 80027
- 4 Open-market sale Chief Commercial Officer sold 462 shares at an average $1.40 ($645)
- 4 Open-market sale President & CEO sold 3,740 shares at an average $1.40 ($5,220)
- 4 Open-market sale CFO, Sec'y & Treasurer sold 971 shares at an average $1.40 ($1,355)
- 4 Open-market buy Director bought 40,000 shares at $1.40 ($55,916)
- 4 Open-market buy Director bought 100,253 shares at $1.36 ($136,585)
- 4 Open-market buy Director bought 75,000 shares at $1.38 ($103,710)
- 4 Open-market buy Director bought 22,500 shares at $1.37 ($30,866)
- 4 Open-market buy Director bought 71,200 shares at an average $1.36 ($97,068)
- 4 Open-market sale Chief Accounting Officer sold 209 shares at an average $1.59 ($333)
- 4 Open-market sale Chief Development Officer sold 431 shares at an average $1.59 ($687)
- 4 Open-market sale Chief Commercial Officer sold 465 shares at an average $1.59 ($741)
- 4 Open-market sale President & CEO sold 3,744 shares at an average $1.59 ($5,966)
- 4 Open-market sale CFO, Sec'y & Treasurer sold 975 shares at an average $1.59 ($1,554)
- 4 Exercise or conversion Director acquired 26,368 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Accounting Officer acquired 880 shares (option exercise)
- 4 Exercise or conversion Director acquired 347,840 shares (option exercise)
- 4 Exercise or conversion Director acquired 86,960 shares (option exercise)
- 4 Exercise or conversion Chief Development Officer acquired 880 shares (option exercise)
- 4 Exercise or conversion Chief Commercial Officer acquired 13,080 shares (option exercise)
Page 5 of 17 · 336 filings